Indoco strikes API marketing deal with DSM
Royal DSM has entered an agreement with India's Indoco Remedies for commercialization of eight Active Pharmaceutical Ingredients (APIs).
Under the agreement, APIs manufactured by Indoco will be marketed and sold by DSM.
The APIs are used to produce pharmaceutical Finished Dosages.
The alliance will employ Indoco's product development and cGMP (current Good Manufacturing Practices) compliant manufacturing capabilities and DSM's market access.
Indoco Remedies is a global pharmaceutical company with a brand portfolio of 120 products in various therapeutic segments, including anti-infectives, anti-diabetics, cardiovascular, ophthalmology, dental care, pain management and respiratory.
DSM Pharmaceutical Products, a business group of Royal DSM, is a global science-based company active in health, nutrition and materials.
Related Insight
Suppliers Directory
Euroscreen - Your Drug Discovery Partner
Euroscreen is a private, Belgian, preclinical-stage, drug discovery and development company targeting G Protein Coupled Receptors (GPCRs) to provide first-in-class small molecule drug candidates for the therapeutic area of metabolism, inflammation and women's health.
Suppliers
Enzo Life Sciences - Cell Analysis, Molecular Biology, Drug Development and Proteostasis
Enzo has been providing enabling technologies for the research, development, manufacture, licensing and marketing of innovative health care products, platforms and services based on molecular and cellular technologies for over 30 years.
Production & Manufacturing > Manufacturing > Suppliers
Scandinavian Packaging - Total Supplier of Plastic Packaging
Scandinavian Packaging has been producing plastic lids and caps specifically for the pharmaceutical and food industry for many years. Scandinavian Packaging is the oldest and one of the largest Scandinavian producers of plastic caps. The company was founded in 1949 and is today is a modern, driven producer of innovative quality plastic caps for the pharmaceutical industry.
Suppliers
FormPipe - Quality Management, CAPA Processes, SOP Management, FDA and GMP Compliance
FormPipe Software AB (publ) is an Enterprise Content Management (ECM) software company. FormPipe Software develop ECM products for structuring information and supply them to major companies, authorities and other organisations.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Farfield Analight 4D Workstation
Published by Farfield Group
White Papers
Introducing the miVac Range
Published by Genevac
White Papers
Tips & Tricks - GPC/SEC: Copolymer Analysis in GPC/SEC 3 - Two-Dimensional Chromatography
Published by Polymer Standards Service
White Papers
Manufacturing Site Rationalisation
Published by Pharmalink Consulting
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.